Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease
worldwide and the leading cause of liver-related morbidity and mortality. We aimed to …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Clinicians can encounter sex and gender disparities in diagnostic and therapeutic
responses. These disparities are noted in epidemiology, pathophysiology, clinical …

Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …

Gender and biological sex impact the pathogenesis of numerous diseases, including
metabolic disorders such as diabetes. In most parts of the world, diabetes is more prevalent …

Objective Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is
associated with an increased risk of incident diabetes, but currently, it is uncertain whether …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of
the world's adult population. Several cohort studies have consistently documented that …

Nonalcoholic fatty liver disease (NAFLD) prevalence in women is increasing worldwide.
Women of reproductive age have lower rates of NAFLD compared with men; however, this …

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases
characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected …